US › Healthcare

Ovid Therapeutics Inc (OVID)

US · Healthcare · Biotechnology

$2.70+0.75%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$733,000

Revenue YoY

-88.3%

Net profit

$-15.0M

EPS

$-0.08

EPS estimate

$-0.10

Net margin

-2,047.6%

EPS came in at -0.08 against a street estimate of -0.10 — a beat of 20.0%.

Key statistics

Market cap

$529.3M

Forward P/E

1.8

P/B

2.55

Book value

$1.14

EPS (TTM)

$-0.21

52-week high

$3.10

52-week low

$1.12

50-day MA

$2.62

200-day MA

$2.24

Beta

0.25

Analyst view

Analysts rate Ovid Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $5.80.

Shareholding

Insiders

6.72%

Institutions

80.34%

Largest institutional holders

Fund	Stake
Eventide Asset Management, LLC	6.05%
HHG PLC	5.49%
RA Capital Management, LLC	5.49%
Affinity Asset Advisors, LLC	5.45%
Adage Capital Partners Gp LLC	3.16%
Federated Hermes Inc	3.05%
Balyasny Asset Management LLC	2.83%
Vanguard Capital Management, LLC	2.69%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ovid Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.